Search

Your search keyword '"Momotow, Jesko"' showing total 17 results
Start Over Author "Momotow, Jesko"
17 results on '"Momotow, Jesko"'

1. Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma

Author

Jacob, Anne Sophie, Kaul, Helen, Fuchs, Michael, Gillessen, Sarah, Kreissl, Stefanie, Pluetschow, Annette, Momotow, Jesko, Schaub, Valdete, Huettmann, Andreas, Haenel, Mathias, Zimmermann, Andreas, Dierlamm, Judith, Meissner, Julia, Mathas, Stephan, Martin, Sonja, Engert, Andreas, Hallek, Michael, Borchmann, Peter, and Lehmann, Clara

Published
2022
Full Text
View/download PDF

2. S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS

Author

Bröckelmann, Paul, primary, Müller, Horst, additional, Gillessen, Sarah, additional, Jacob, Anne Sophie, additional, Momotow, Jesko, additional, Damaschin, Carla, additional, Ferdinandus, Justin, additional, Yang, Xiaoqin, additional, Fuchs, Michael, additional, Kobe, Carsten, additional, Eich, Hans T., additional, Engert, Andreas, additional, Borchmann, Peter, additional, and von Tresckow, Bastian, additional

Published
2023
Full Text
View/download PDF

3. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

Author

Sasse, Stephanie, primary, Bröckelmann, Paul Jan, additional, Momotow, Jesko, additional, Plütschow, Annette, additional, Hüttmann, Andreas, additional, Basara, Nadezda, additional, Koenecke, Christian, additional, Martin, Sonja, additional, Bentz, Martin, additional, Grosse-Thie, Christina, additional, Thorspecken, Sven, additional, de Wit, Maike, additional, Kobe, Carsten, additional, Dietlein, Markus, additional, Tresckow, Bastian von, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2022
Full Text
View/download PDF

4. Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis

Author

Momotow, Jesko, Buehnen, Ina, Trautmann-Grill, Karolin, Kobbe, Guido, Hahn, Dennis, Schroers, Roland, Heinrich, Bernhard, Gaska, Tobias, Forstbauer, Helmut, Schmidt, Burkhard, Boger, Regina, Huettmann, Andreas, Heil, Gerhard, Kraemer, Doris M., Krueger, William, Zeremski, Vanja, Grobe, Norbert, Jentsch-Ullrich, Kathleen, Griesinger, Frank, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Engert, Andreas, Broeckelmann, Paul J., Momotow, Jesko, Buehnen, Ina, Trautmann-Grill, Karolin, Kobbe, Guido, Hahn, Dennis, Schroers, Roland, Heinrich, Bernhard, Gaska, Tobias, Forstbauer, Helmut, Schmidt, Burkhard, Boger, Regina, Huettmann, Andreas, Heil, Gerhard, Kraemer, Doris M., Krueger, William, Zeremski, Vanja, Grobe, Norbert, Jentsch-Ullrich, Kathleen, Griesinger, Frank, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Engert, Andreas, and Broeckelmann, Paul J.

Published
2022

5. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

Author

Sasse, Stephanie, Brockelmann, Paul Jan, Momotow, Jesko, Plutschow, Annette, Huttmann, Andreas, Basara, Nadezda, Koenecke, Christian, Martin, Sonja, Bentz, Martin, Grosse-Thie, Christina, Thorspecken, Sven, de Wit, Maike, Kobe, Carsten, Dietlein, Markus, v Tresckow, Bastian, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, Sasse, Stephanie, Brockelmann, Paul Jan, Momotow, Jesko, Plutschow, Annette, Huttmann, Andreas, Basara, Nadezda, Koenecke, Christian, Martin, Sonja, Bentz, Martin, Grosse-Thie, Christina, Thorspecken, Sven, de Wit, Maike, Kobe, Carsten, Dietlein, Markus, v Tresckow, Bastian, Fuchs, Michael, Borchmann, Peter, and Engert, Andreas

Abstract

In patients with relapse of classical Hodgkin lymphoma (cHL) after autologous stem cell transplant, brentuximab vedotin and anti-PD1 treatment, the outcome is poor. To assess the efficacy of the bispecific anti-CD30/CD16A, NK-cell engaging antibody AFM13 and to select the optimal treatment schedule (arm A-C), we initiated a randomized two-stage phase II trial (NCT02321592). Due to slow recruitment, the trial was terminated after treatment of 25 patients. Treatment with AFM13 was well tolerated: only two treatment-associated serious adverse events (SAEs) were reported; all SAEs resolved completely. With an objective response rate (ORR) of 16.7% (1/5 in arm A, 1/11 in arm B, and 2/8 in arm C) and a 12-month progression-free survival (PFS) of 12.6% (95% CI 3.2-28.9), treatment efficacy of AFM13 monotherapy in all evaluable patients was modest. The continuous application schedule (arm C) might be more effective, but the visit schedule should be better aligned with patients' daily life.

Published
2022

6. Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis

Author

Momotow, Jesko, primary, Bühnen, Ina, additional, Trautmann‐Grill, Karolin, additional, Kobbe, Guido, additional, Hahn, Dennis, additional, Schroers, Roland, additional, Heinrich, Bernhard, additional, Gaska, Tobias, additional, Forstbauer, Helmut, additional, Schmidt, Burkhard, additional, Boger, Regina, additional, Hüttmann, Andreas, additional, Heil, Gerhard, additional, Kraemer, Doris M., additional, Krüger, William, additional, Zeremski, Vanja, additional, Grobe, Norbert, additional, Jentsch‐Ullrich, Kathleen, additional, Griesinger, Frank, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and Bröckelmann, Paul J., additional

Published
2022
Full Text
View/download PDF

7. Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Author

Momotow, Jesko, primary, Bühnen, Ina, additional, Trautmann-Grill, Karolin, additional, Kobbe, Guido, additional, Wilhelm, Martin, additional, Heinrich, Bernhard, additional, Gaska, Tobias, additional, Forstbauer, Helmut, additional, Schmidt, Burkhard, additional, Hüttmann, Andreas, additional, Heil, Gerhard, additional, Kraemer, Doris M., additional, Krüger, William Hermann, additional, Zeremski, Vanja, additional, Grobe, Norbert, additional, Jentsch-Ulrich, Kathleen, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and Bröckelmann, Paul J, additional

Published
2021
Full Text
View/download PDF

8. Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients

Author

Momotow, Jesko, Borchmann, Sven, Eichenauer, Dennis A., Engert, Andreas, Sasse, Stephanie, Momotow, Jesko, Borchmann, Sven, Eichenauer, Dennis A., Engert, Andreas, and Sasse, Stephanie

Abstract

Hodgkin lymphoma (HL) is a rare malignancy accounting for roughly 15% of all lymphomas and mostly affecting young patients. A second peak is seen in patients above 60 years of age. The history of HL treatment represents a remarkable success story in which HL has turned from an incurable disease to a neoplasm with an excellent prognosis. First-line treatment with stage-adapted treatment consisting of chemotherapy and/or radiotherapy results in cure rates of approximately 80%. Second-line treatment mostly consists of intensive salvage chemotherapy followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). Novel approaches such as antibody drug conjugates and immunomodulatory drugs have shown impressive results in clinical trials in refractory and relapsed HL and are now increasingly implemented in earlier treatment lines. This review gives a comprehensive overview on HL addressing epidemiology, pathophysiology and current treatment options as well as recent developments and perspectives.

Published
2021

11. AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Author

Sasse, Stephanie, primary, Momotow, Jesko, additional, Plütschow, Annette, additional, Hüttmann, Andreas, additional, Basara, Nadezda, additional, Koenecke, Christian, additional, Martin, Sonja, additional, Bentz, Martin, additional, Grosse-Thie, Christina, additional, Thorspecken, Sven, additional, de Wit, Maike, additional, Kobe, Carsten, additional, Dietlein, Markus, additional, von Tresckow, Bastian, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

17. Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.

Author

Hude I, Sasse S, Bröckelmann PJ, von Tresckow B, Momotow J, Engert A, and Borchmann S

Subjects
Adult, Autografts, Disease-Free Survival, Eosinophils, Female, Humans, Leukocyte Count, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Survival Rate, Hematopoietic Stem Cell Transplantation, Hodgkin Disease blood, Hodgkin Disease mortality, Hodgkin Disease therapy, Nivolumab administration & dosage, Programmed Cell Death 1 Receptor antagonists & inhibitors
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results